1. Home
  2. ARMP vs MATH Comparison

ARMP vs MATH Comparison

Compare ARMP & MATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARMP
  • MATH
  • Stock Information
  • Founded
  • ARMP N/A
  • MATH 2015
  • Country
  • ARMP United States
  • MATH Hong Kong
  • Employees
  • ARMP N/A
  • MATH N/A
  • Industry
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • MATH Finance/Investors Services
  • Sector
  • ARMP Health Care
  • MATH Finance
  • Exchange
  • ARMP Nasdaq
  • MATH Nasdaq
  • Market Cap
  • ARMP 52.1M
  • MATH 60.8M
  • IPO Year
  • ARMP N/A
  • MATH N/A
  • Fundamental
  • Price
  • ARMP $2.22
  • MATH $3.60
  • Analyst Decision
  • ARMP Strong Buy
  • MATH
  • Analyst Count
  • ARMP 1
  • MATH 0
  • Target Price
  • ARMP $9.00
  • MATH N/A
  • AVG Volume (30 Days)
  • ARMP 18.4K
  • MATH 200.0K
  • Earning Date
  • ARMP 08-12-2025
  • MATH 08-26-2025
  • Dividend Yield
  • ARMP N/A
  • MATH N/A
  • EPS Growth
  • ARMP N/A
  • MATH N/A
  • EPS
  • ARMP N/A
  • MATH 0.17
  • Revenue
  • ARMP $4,699,000.00
  • MATH $31,399,049.00
  • Revenue This Year
  • ARMP $8.43
  • MATH N/A
  • Revenue Next Year
  • ARMP N/A
  • MATH N/A
  • P/E Ratio
  • ARMP N/A
  • MATH $21.34
  • Revenue Growth
  • ARMP 14.24
  • MATH 291.58
  • 52 Week Low
  • ARMP $0.90
  • MATH $0.80
  • 52 Week High
  • ARMP $3.42
  • MATH $4.17
  • Technical
  • Relative Strength Index (RSI)
  • ARMP 63.56
  • MATH 61.32
  • Support Level
  • ARMP $1.93
  • MATH $3.55
  • Resistance Level
  • ARMP $2.24
  • MATH $3.97
  • Average True Range (ATR)
  • ARMP 0.16
  • MATH 0.32
  • MACD
  • ARMP 0.03
  • MATH 0.03
  • Stochastic Oscillator
  • ARMP 104.55
  • MATH 83.49

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.

Share on Social Networks: